With the shares down 60% following Fate's announced pipeline prioritization and Janssen termination, the "damage has largely been done and there is an opportunity for value-based, longer-term investors to step in," Nochomovitz tells investors in a research note. Question 3: What about the average return after a rise if you wait for a while? The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its . All rights reserved. Fate Therapeutics does not have a long track record of dividend growth. Case 1: Fate Therapeutics stock drops by -5% or more in a week, Case 2: Fate Therapeutics stock rises by 5% or more in a week. Following the acquisition, the director now owns 246,139 shares in the company, valued at $1,395,608.13. 17.34% of the stock is owned by insiders. Moderna leans into oncology with CytomX deal worth up to $1.2B Fate ends potential $3B Janssen partnership. It is engaged in the development of programmed cellular immunotherapies for cancer and immune. She looks for companies that are changing the . The definitive agreement will see the payment of up to $1bn to Exonics' equity holders if future development and regulatory milestones are met for certain programmes. FATE stock is also up a massive 18x from levels of $6 seen in early 2018, three years ago. Envestnet Asset Management Inc. boosted its stake in Fate Therapeutics by 20.0% in the 1st quarter. | March 3, 2023 Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Scott Wolchko, president and chief executive officer of Fate Therapeutics, touted the partnership with Janssen. Fate Therapeutics Market Cap Make that two consecutive days of riding the momentum from the Juno Therapeutics acquisition. Is UnitedHealth Stock A Better Pick Over This Healthcare Facility Company? The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while its up 13% over the last ten trading days, and we believe the rally may continue in the near term. The company said late Thursday it is working on a treatment for a blood . Market Volatility To Continue Its The Economy (Stupid)! Fate Therapeutics is funded by 8 investors. The early stage company is also eligible to receive up to $1.8 billion in development and. Shares of FATE stock opened at $6.11 on Thursday. Fate Therapeutics does not currently pay a dividend. Last updated: Feb 26, 2023 Powered by IT Spend by Aberdeen This year, Fate Therapeutics is projected to spend $682.2K on IT, according to Aberdeen. Opinions expressed by Forbes Contributors are their own. Fate Therapeutics has an overall rating of 2.9 out of 5, based on over 76 reviews left anonymously by employees. View FATE analyst ratings or view top-rated stocks. Our daily ratings and market update email newsletter. The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. If you wish to serve as lead plaintiff, you . In fact, the average price estimate for FATE stock is $112, reflecting a large 40% premium to the current market price of $79. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The biotech shared an interim peek of data. This company's $6.7 billion market cap at the moment assumes a great deal of success down the road. Identify stocks that meet your criteria using seven unique stock screeners. General & Administrative expenses jumped to $12.5 million from $7.7 million in the year-ago. Current Cathie Wood Portfolio 2023. BMO Capital Markets cut shares of Fate Therapeutics from an outperform rating to a market perform rating and lowered their target price for the stock from $20.00 to $7.00 in a research note on Friday, January 6th. The company is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Fate Therapeutics stock chances of a rise after a fall. A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. Some Fun Scenarios, FAQs & Making Sense of Fate Therapeutics Stock Movements: Question 1: Is the average return for Fate Therapeutics stock higher after a drop? In related news, CFO Edward J. Dulac III sold 7,331 shares of the companys stock in a transaction dated Tuesday, January 10th. View which stocks are hot on social media with MarketBeat's trending stocks report. Press Releases. Fate Therapeutics' stock was trading at $10.09 at the beginning of the year. According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). The company's quarterly revenue was up 159.9% on a year-over-year basis. 17.34% of the stock of Fate Therapeutics is held by insiders. Here's what Wall Street expects from Fate Therapeutics's earnings report, Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates, Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M, FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus, Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $26.14, NK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics Scenario, Induced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028, Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7%, Natural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028, Natural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028, FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit, Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline, Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session, Needham Reaffirms Their Buy Rating on G1 Therapeutics (GTHX), Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results, ALERT: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE, CLASS ACTION UPDATE for AVYA, FATE and PHI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, CLASS ACTION UPDATE for ENVX, YMAB and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, view top-rated stocks among Wall Street analysts, 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Following the sale, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. 40% of employees would recommend working at Fate Therapeutics to a friend and 22% have a positive outlook for the business. The firm has a fifty day moving average of $7.23 and a 200-day moving average of $17.23. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. Investigator-assessed ORR was 11.4% in patients with NPCB, 16.9% with PCB, and 25.0% in CPI-nave. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. Will Boston Scientific Stock See Higher Levels? It has seen positive findings from early trials for FT500, preventing disease progression for 11 out of 15 patients, something that has kept the stock price buzzing of late. Following the completion of the transaction, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Going by historical performance, there is roughly an equal chance of a rise or fall in FATE stock over the next month. Purchases New Holdings in Ball Co. (NYSE:BALL), Blueshift Asset Management LLC Sells 21,016 Shares of Dell Technologies Inc. (NYSE:DELL), Cary Street Partners Investment Advisory LLC Has $126,000 Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC). Fate could receive another $3 billion in various conditional payments tied to regulatory and sales milestones if all goes to plan, though those payments may never materialize. During the same quarter in the prior year, the firm posted ($0.72) EPS. About FT516 FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line . With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! On corrections down, there will be some support from the lines at $63.99 and $66.95. HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical companys stock valued at $714,000 after purchasing an additional 1,016 shares during the last quarter. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Published: Apr 03, 2020 "From speaking to management, we think this is exactly the type of deal [Fate] was looking for," wrote Cantor Fitzgerald analyst Alethia Young, referring to a back-loaded agreement that gives the company the chance to keep some rights to the programs in the alliance. The company employs 449 workers across the globe. In other Fate Therapeutics news, Director John Mendlein bought 88,048 shares of Fate Therapeutics stock in a transaction that occurred on Wednesday, January 11th. By Alex Keown. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Twitter Is Just One Reason Why, Gamma Mama! Fate Therapeutics hat am 01.03.2023 das Zahlenwerk zum am 31.12.2022 ausgelaufenen Quartal vorgelegt. Earnings for Fate Therapeutics are expected to grow in the coming year, from ($2.16) to ($2.13) per share. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. Jeereddi Investments LP Increases Position in Alphabet Inc. Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $91,000. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. A class action has already been filed. Es wurde ein Verlust je Aktie von 0 . Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, By Christopher Newman and Jonathan Gardner , A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric A, EUCOPE adds nine new innovative members to its network, From EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board, Vial Announces the Addition of Dr. Rajat N Agrawal to their Ophthalmology CRO Scientific Advis, By signing up to receive our newsletter, you agree to our, disrupting study enrollment and treatment, Bayer backs cell therapy startup with $215M in funding, Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work, 5 questions facing the pharma industry in 2023, FDA clears Intellia to start US tests of in vivo gene editing drug, Novartis takes step toward expanding supply of in-demand cancer drug, Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients, Exelixis reports trial failure for cancer drug combination, How to Implement a Healthy Content Moderation Strategy, How To Build Affordability Programs With Real-time Data, FDA has new power to hold drugmakers accountable. Purchases New Holdings in Ball Co. Kroger (NYSE:KR) Shares Gap Up on Better-Than-Expected Earnings, AlphaCrest Capital Management LLC Trims Position in Best Buy Co., Inc. (NYSE:BBY), AlphaCrest Capital Management LLC Sells 26,238 Shares of Hormel Foods Co. (NYSE:HRL), Burlington Stores, Inc. (NYSE:BURL) Shares Sold by Eaton Vance Management, Tudor Investment Corp Et Al Increases Holdings in Artivion, Inc. (NYSE:AORT), BlackRock Inc. FATE - Fate Therapeutics, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. These companies have yet to prove off-the-shelf approaches can match, or surpass, what has been seen with CAR-T without triggering serious or potentially deadly immune reactions. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. However, any positive outcome on the trials related to the companys solid tumor treatment candidates will likely result in stock price growth. AXSM Signals & Forecast. It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. Sign in to your free account to enjoy all that MarketBeat has to offer. Powered by Madgex Job Board Software. The firm owned 161,373 shares of the biopharmaceutical companys stock after selling 59,987 shares during the quarter. The Axsome Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Owens Corning (NYSE:OC) Shares Sold by Capital Fund Management S.A. Nucor Co. (NYSE:NUE) Shares Sold by Blueshift Asset Management LLC, Stratasys Ltd. (NASDAQ:SSYS) Stock Holdings Lifted by AlphaCrest Capital Management LLC, Blueshift Asset Management LLC Lowers Stock Position in Urban Outfitters, Inc. (NASDAQ:URBN). Analysts like Fate Therapeutics less than other Medical companies. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. AlphaCrest Capital Management LLC Trims Position in Best Buy Co., Inc. AlphaCrest Capital Management LLC Sells 26,238 Shares of Hormel Foods Co. Burlington Stores, Inc. Shares Sold by Eaton Vance Management. One share of FATE stock can currently be purchased for approximately $6.11. You may opt-out by. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. sharewise - Stocks and the Wisdom of the crowd. The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. In other news, CFO Edward J. Dulac III sold 7,331 shares of the businesss stock in a transaction that occurred on Tuesday, January 10th. Zscaler, Inc Plummets, Is It Time To Buy The Dip? Specifically, ARK Genomic Revolution ETF ( NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF ( NYSEARCA: ARKK) bought 186,114 shares. Transforming the lives of patients with cancer and immune disorders. Fate turns cells from donors into induced pluripotent stem cells, which in turn can be re-engineered into a variety of different cells. The disclosure for this purchase can be found here. See allTrefis Price EstimatesandDownloadTrefis Datahere, Whats behind Trefis? Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. New U.S. cancer drug prices rise 53% in five years - report. It didn't provide specific details. It's an emerging field of research that's still in its early stages. In other Fate Therapeutics news, CEO J Scott Wolchko sold 45,907 shares of the firms stock in a transaction on Tuesday, January 10th. Large investors have recently added to or reduced their stakes in the company. After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock (NASDAQ Facebook. The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement. Fate Therapeutics, Inc. ( NASDAQ:FATE - Get Rating )'s stock price shot up 7.4% during mid-day trading on Wednesday after the company announced . Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece,a roughly 47% premium to Fate's $21.07 closing price on Thursday. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. The stock has a market cap of . Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited. MACHINE LEARNING ENGINE try it yourself: IF FATE stock moved by -5% over five trading days, THEN over the next twenty-one trading days, FATE stock moves an average of 6%, which implies an excess return of 4% compared to the S&P500. But pharma has made notable investments in the work, which could lead to treatments that are quicker and less costly to produce than their autologous counterparts. Adjusted EPS was $2.04 - up 92% year-on-year - and H1'22 EPS was reported. Drug price reforms and regulatory scrutiny present challenges for large drugmakers, although successes in Alzheimers and obesity have brought new opportunities, too. About Fate Therapeutics, Inc. FATE Fate Therapeutics Inc 6,209 $6.11 $0.02 (0.33%) Today Market Cap $583.99M Volume (M) 1.52M 52-Wk High $43.12 52-Wk Low $4.02 About Feed Sentiment Fundamentals News There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Sentiment Score Message Volume Score Disclaimer: This is informational only. contact@marketbeat.com However, the company saw a 62% growth in total shares outstanding due to share issuances, resulting in only a 61% growth in revenue per share to $0.16 in 2019, compared to $0.10 in 2017. Guggenheim cut shares of Fate Therapeutics from a buy rating to a neutral rating in a research note on Tuesday, January 3rd. Fate is one of a group of companies advancing an "off-the-shelf" cell therapy approach, which utilizes cells taken from healthy donors. Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Additionally, Fate has the right to co-commercialize the candidates should they be approved and share equally in profits and losses, the company said in its announcement. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. Fate is all of that. Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. Now, is FATE stock poised to gain further? Shares climbed about 20%, to around $25 apiece, in pre-market trading Friday. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical companys stock worth $260,000 after buying an additional 986 shares during the last quarter. View the best growth stocks for 2023 here. Lazard Asset Management LLC lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Rating) by 27.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Now, is FATE stock poised to gain further? The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. Its pretty powerful to test the trend for yourself for Fate Therapeutics stock by changing the inputs in the charts above. What is a Good Dividend Yield? Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST See our analysis on Fate Therapeutics Stock Chances of Rise for more details. The. The partnership doesn't include any of the other treatments currently in Fate's pipeline. Our dashboard, What Factors Drove 1771% Change in Fate Therapeutics Stock between 2017 end and now?, has the underlying numbers. Fate is working toward a class of treatment that is based on NK cells. The company is currently working on multiple programs, including FT516 for the treatment of acute myeloid leukemia and B-cell lymphoma, FT596 to treat B-cell lymphoma, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. This suggests a possible upside of 304.1% from the stock's current price. How many employees does Fate Therapeutics have? While FATE stock may be overvalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. The P/E ratio of Fate Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Stock analysis for Fate Therapeutics Inc (FATE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. Former Qualcomm CEO Steven Mollenkopf, who retired in June 2021, pulled in total compensation of $69 million last year, which ranked highest among CEOs of the region's 100 publicly traded companies. When that time comes, Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. Tesla Investors Arent Impressed With Elon Musk. [Updated: 3/30/2021] Can FATE Stock Rebound? Fate Therapeutics is registered under the ticker NASDAQ:FATE . Five Day: FATE 16%, vs. S&P500 4%; Outperformed market, Ten Day: FATE 13%, vs. S&P500 1.8%; Outperformed market. (Ad). You may opt-out by. Answer: The average return after a rise is understandably lower than a fall as detailed in the previous question. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. Separately, Fate Therapeutics Chief Scientific Officer - Daniel Shoemaker - will be leaving the company in June this year, and this development has likely hurt the stock. The shares were bought at an average price of $5.67 per share, with a total value of $499,232.16. If response rates for its treatments fall, as is usually the case in cancer trials, this stock . Fate Therapeutics has received a consensus rating of Hold. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively. Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. The decline is driven in part by the broader sell-off in high growth stocks. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. It appears so. Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. Get short term trading ideas from the MarketBeat Idea Engine. In-depth profiles and analysis for 20,000 public companies. Also, Director John Mendlein purchased 88,048 shares of the businesss stock in a transaction on Wednesday, January 11th. Horizon Therapeutics becomes target of acquisition by pharma giants. Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE.". Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. American Consumer News, LLC dba MarketBeat 2010-2023. What other stocks do shareholders of Fate Therapeutics own? Get Fate Therapeutics Inc (FATE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Lazard Asset Management LLC Benzinga 4 days ago FATE SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fate. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Zscaler, Inc Plummets, Is It Time To Buy The Dip? Looking at the recent rally, the 9% rise for FATE stock over the last five days compares with a 0.7% growth seen in the broader S&P 500 index. Lazard Asset Management LLC Raises Stake in CDW Co. (NASDAQ:CDW), Verition Fund Management LLC Raises Stock Position in Teradyne, Inc. (NASDAQ:TER), Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE). Currency in USD Follow 2W 10W 9M 6.11 +0.02 (+0.33%) At close: 04:00PM EST 6.29 +0.18 (+2.95%) After hours: 05:58PM EST. Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Segall Bryant & Hamill LLC's holdings in Fate Therapeutics [] And the recent stock price growth means that some of the positives are already priced in at the current price of $114. Fate Therapeutics (NASDAQ:FATE - Get Rating) had its price target upped by equities research analysts at Citigroup from $9.00 to $10.00 in a report issued on Thursday, The Fly reports. Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high.